

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNISOUND AI TECHNOLOGY CO., LTD.

雲知聲智能科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9678)

VOLUNTARY ANNOUNCEMENT MEDICAL INTELLIGENCE BUSINESS DEVELOPMENTS

This announcement is made by Unisound AI Technology Co., Ltd. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company of its latest business developments.

I. Secured Multiple Healthcare Benchmark Projects, with Total Contract Value of Approximately RMB100 Million

Since the release of “U2-Med Tri-Medical LLM”, the industry’s first professional large model for the medical, medical insurance (including commercial insurance), and pharmaceutical sectors, the Company’s vertical large model, trained based on its proprietary U2 foundation large model, has been accelerating the conversion of its technological advantages into commercial results. Recently, the Company has successively won bids for multiple benchmark projects in the intelligent healthcare field:

- (i) Multiple intelligent healthcare projects of leading Grade-A tertiary hospitals: Leveraging its mature model capabilities and delivery system, the Company successfully won bids for large model-based intelligent healthcare projects from multiple leading Grade-A tertiary hospitals, covering various types of medical institutions such as pediatric specialty hospitals and regional comprehensive medical centers. It focused on the in-hospital implementation of capabilities such as vertical large medical models, intelligent medical records, medical data governance, and intelligent services;
- (ii) Intelligent fund supervision project for a leading insurance institution: The Company successfully won the bid for an intelligent fund supervision project of a leading insurance institution. It leveraged the capabilities of its vertical large

model in medical insurance to develop a professional intelligent supervision solution that integrates pre-event warning, in-event monitoring, and post-event traceability, thereby helping to transform the supervision model from traditional manual spot checks to an intelligent and precise approach; and

- (iii) Regional medical intelligence project: The Company won the bid for a regional medical intelligence project, where, leveraging the data middle platform as its foundation, it systematically integrated the capabilities of large model products, such as medical record generation, AI-assisted consultation, clinical decision support, and intelligent quality control, into diagnosis and treatment services, referral coordination, convenient medical access, industry supervision and more, thereby establishing a regional intelligent system that connects data, diagnosis and treatment, services, and supervision.

The total contract value of the above projects, amounting to approximately RMB100 million, demonstrates the market's high recognition of the Company's technical strength and engineering delivery capabilities in the field of vertical large medical models.

II. Project Significance

From a technical perspective, large models are reshaping the underlying capabilities of the healthcare industry. The above-mentioned projects cover key scenarios such as in-hospital diagnosis and treatment, fund supervision, and regional data governance, signifying that artificial intelligence is beginning to enter core business processes on a large scale in the highly specialized field of healthcare. The continuous validation and iteration of the Company's vertical large medical model in real-world scenarios will further consolidate its technological leadership position in the intelligitization process of the industry.

From a commercial perspective, the coordinated development of medical care, medical insurance, and commercial insurance is an important direction for the reform of the medical and healthcare system. The above-mentioned projects cover all segments of the industry chain, demonstrating that the Company's business strategy is highly aligned with the direction of the national "tri-medical linkage" reform. The regional medical projects have further verified the capability for large-scale replication from single institutions to entire regions. The Company will use benchmark projects as demonstration cases to establish a replicable and scalable paradigm for regional smart healthcare development, opening up a vast market for medical artificial intelligence to expand from individual sites to entire regions.

In the longer term, the uneven distribution of quality medical resources remains a long-standing issue. The aforementioned projects promote the extension of quality medical capabilities to grassroots and regional levels, allowing the public to enjoy quality medical services nearby, which is a practice of the “AI for Good” philosophy. The Company will continue to transform cutting-edge artificial intelligence capabilities into inclusive and accessible medical and health services, ensuring that technological progress truly benefits the people’s well-being.

III. Outlook

With the successive implementation of the aforementioned benchmark projects, the commercialization process of the Company’s large medical model will further accelerate. The real-world business data accumulated during project execution will continuously feed back into model iteration, creating a virtuous cycle. In the future, the Company will continue to deepen the application and innovation of large models in the pan-medical field, serving more medical institutions with standardized and replicable delivery capabilities to facilitate the intelligent upgrade of the healthcare industry, and injecting long-term momentum for the continuous release and commercial realization of the Company’s high-value Tokens.

By Order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei

Executive Director and Chief Executive Officer

Beijing, the PRC
September 7, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Liang Jia’en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; and (ii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.